Ignite Creation Date:
2024-05-06 @ 4:02 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04843085
Status:
UNKNOWN
Last Update Posted:
2021-04-13
First Post:
2020-12-17
Brief Title:
Proteomic Characterization of Aggressive Oligodendrogliomas
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Proteomic Characterization of Aggressive Oligodendrogliomas
Status:
UNKNOWN
Status Verified Date:
2020-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROGLIO
Brief Summary:
Oligodendrogliomas represent a distinct subgroup of adult gliomas characterized by specific molecular alterations 1p19q codeletion mutations of IDH TERT promoter CIC FUBP1 These tumors account for 5 to 10 of adult gliomas and are of special relevance in the neuro-oncology field because of their frequent chemosensitivity Louis et al 2016 The genetics of oligodendrogliomas is relatively well characterized but the mechanisms of oncogenesis for these tumors are poorly understood
Although oligodendrogliomas prognosis is usually better than that of other adult glioma subtypes it remains heterogeneous and there is no effective treatment at recurrence after radiotherapy and chemotherapy Our recent work conducted within the INCa-funded national POLA network has related this clinical heterogeneity to inter-tumoral heterogeneity Based on a transcriptomic analysis of a large series of oligodendroglial gliomas we identified 3 subgroups the most aggressive group being characterized by aggressive clinical and molecular pattern Recent studies however have shown a relatively low level of concordance between mRNA and protein expression emphasizing the need to use proteomic-based approaches to better understand tumor biology Taking advantage of the POLA cohort we propose to expand our previous analysis by integrating a proteomic analysis of oligodendrogliomas
The aim of this project is to identify drivers of oligodendroglioma subgroups among which potential druggable targets ie receptors metabolism effectors For this purpose the proteomic profiles of 90 oligodendrogliomas will be generated and integrated with transcriptomic genomic and methylation profiles in order to identify signaling pathways specifically associated with each subtype especially with the most aggressive one Associations will be explored between candidate signaling pathways expression and clinical outcomes survival progression-free survival objective response The relevance of the 2 most promising candidate signaling pathways will be assessed in vitro and in vivo using genetically relevant mouse and xenograft models
Our project will identify targetable oncogenic pathways associated with poor prognosis that could lead to new therapeutic strategies
Although oligodendrogliomas prognosis is usually better than that of other adult glioma subtypes it remains heterogeneous and there is no effective treatment at recurrence after radiotherapy and chemotherapy Our recent work conducted within the INCa-funded national POLA network has related this clinical heterogeneity to inter-tumoral heterogeneity Based on a transcriptomic analysis of a large series of oligodendroglial gliomas we identified 3 subgroups the most aggressive group being characterized by aggressive clinical and molecular pattern Recent studies however have shown a relatively low level of concordance between mRNA and protein expression emphasizing the need to use proteomic-based approaches to better understand tumor biology Taking advantage of the POLA cohort we propose to expand our previous analysis by integrating a proteomic analysis of oligodendrogliomas
The aim of this project is to identify drivers of oligodendroglioma subgroups among which potential druggable targets ie receptors metabolism effectors For this purpose the proteomic profiles of 90 oligodendrogliomas will be generated and integrated with transcriptomic genomic and methylation profiles in order to identify signaling pathways specifically associated with each subtype especially with the most aggressive one Associations will be explored between candidate signaling pathways expression and clinical outcomes survival progression-free survival objective response The relevance of the 2 most promising candidate signaling pathways will be assessed in vitro and in vivo using genetically relevant mouse and xenograft models
Our project will identify targetable oncogenic pathways associated with poor prognosis that could lead to new therapeutic strategies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None